Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 17.64M P/E - EPS this Y 55.80% Ern Qtrly Grth -
Income -32.79M Forward P/E -0.84 EPS next Y 68.80% 50D Avg Chg -36.00%
Sales 2.87M PEG -0.01 EPS past 5Y - 200D Avg Chg -45.00%
Dividend N/A Price/Book N/A EPS next 5Y 59.10% 52W High Chg -77.00%
Recommedations 2.30 Quick Ratio 0.05 Shares Outstanding 25.97M 52W Low Chg 19.00%
Insider Own 40.26% ROA -101.84% Shares Float 17.25M Beta 1.37
Inst Own 10.24% ROE - Shares Shorted/Prior 196.23K/96.97K Price 0.68
Gross Margin - Profit Margin - Avg. Volume 816,460 Target Price 10.50
Oper. Margin -1,086.39% Earnings Date Mar 29 Volume 1,375,999 Change -4.35%
About Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Aridis Pharmaceuticals Inc. News
01/25/23 Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
01/17/23 New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
12/28/22 Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
12/12/22 (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12/12/22 Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12/05/22 Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
07:00 AM Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
11/22/22 Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
11/21/22 Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
11/21/22 Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
10/12/22 DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study
10/11/22 scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
10/11/22 Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
10/04/22 Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study
09/27/22 Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock
09/26/22 Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock
09/21/22 Wave Therapeutics (WVE) Up on Update From Huntington's Study
09/19/22 Intellia (NTLA) Reports Positive Results for CRISPR Candidates
09/19/22 bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
08/16/22 Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
ARDS Chatroom

User Image moehemayed2017 Posted - 42 minutes from now

$ARDS

User Image nicksaviking Posted - 27 minutes from now

$ARDS I don't follow why everyone is talking about long positions. Looking at the charts, this thing seems to pop above $1 about once a week, doesn't it?

User Image Dblbarrel Posted - 2 minutes ago

$ARDS will add slowly over the next few months. It will pop eventually

User Image Willoughbyschoice Posted - 29 minutes ago

$ARDS everytine I have one more example for the SEC keep it postavtive dont let them take your shares

User Image Willoughbyschoice Posted - 30 minutes ago

$ARDS again his bs!!!

User Image cardinals420 Posted - 33 minutes ago

$ARDS

User Image tradingsniper18 Posted - 33 minutes ago

$ARDS All of my long friends in here have been rather quiet. I feel your pain guys it seems the longer we hold the worse is gets... Our day will come eventually

User Image teteboy77 Posted - 50 minutes ago

$ARDS Falling knife....

User Image kaefer Posted - 52 minutes ago

$ARDS

User Image Joe215 Posted - 53 minutes ago

$ARDS call me crazy but I'm still adding here. It will take some time to bounce but that RSI is just too wet and makes me hrny af

User Image PayMyBulls Posted - 53 minutes ago

$ARDS still here and loving the 2 hours now of good consolidation.

User Image 2pumps1dump Posted - 1 hour ago

$ARDS accumulate

User Image UltraBearIsBorn Posted - 1 hour ago

$ARDS i like this stock, it dips hard, but also rips hard (next).

User Image VetDadDayTrader Posted - 1 hour ago

$ARDS after watching this ticker for the past week, it certainly has the tendency to dip hard and then rip back up. That .60 price earlier was a great example. Came right back up. I will be looking for that next deep dip to buy in.

User Image Willoughbyschoice Posted - 1 hour ago

$ARDS this shit again!!

User Image KING_of_the_Trade Posted - 1 hour ago

$ARDS 0.80 average... Guess he either deeply red and pump faking to be a short, or he took the major loss and has an axe to grind against whomeever will read his words. Either way, funny shyt. LET'S GO!

User Image teteboy77 Posted - 1 hour ago

$ARDS oops...

User Image KING_of_the_Trade Posted - 1 hour ago

$ARDS

User Image lilrob91 Posted - 1 hour ago

$ARDS told yall bulls

User Image KING_of_the_Trade Posted - 1 hour ago

$ARDS I've been in...

User Image TopGs Posted - 2 hours ago

$ARDS this is the loading zone.

User Image TopGs Posted - 2 hours ago

$ARDS shorts trynna steal some shares

User Image Willoughbyschoice Posted - 2 hours ago

$ARDS if you havent gotten in nows the time were going to atleast .90 today

User Image StockProphercy Posted - 2 hours ago

$ARDS $2 coming

User Image hidjay01 Posted - 2 hours ago

$ARDS go to 2 !!!!

User Image Willoughbyschoice Posted - 2 hours ago

$ARDS this is amazing as well

User Image Willoughbyschoice Posted - 2 hours ago

$ARDS

User Image Willoughbyschoice Posted - 2 hours ago

$ARDS people need to remeber this guy too 190 million to help their phase 3 study

User Image Sammy41020 Posted - 2 hours ago

$ARDS investor observer says 2.00 to 19.00

User Image Willoughbyschoice Posted - 2 hours ago

$ARDS cystic Fibroris gave 4.8 mill to ArDS for another new research

Analyst Ratings
Maxim Group Hold Aug 16, 22
HC Wainwright & Co. Buy Jul 20, 21
H.C. Wainwright Buy May 15, 20
Roth Capital Buy Feb 19, 20
H.C. Wainwright Buy Dec 30, 19
Northcoast Research Outperform Sep 10, 18
Laidlaw & Co. Buy Sep 10, 18
Cantor Fitzgerald Overweight Sep 10, 18